Devgen’s mission is to enable farmers to sustainably grow more food on less land, with less water, agrochemicals and labor.
Devgen uses advanced biotechnology and molecular breeding technology to make high yielding seeds and crop protection solutions with a superior environmental profile.
Devgen brings this technology to the market in the world’s major food and feed crops through two complementary strategies:
- Licensing Devgen technology for use in corn, cotton and soy and selected other crops in exchange for R&D funding, and milestone and royalty payments.
- Producing and selling its premium hybrid seeds in major field crops such as rice, sunflower, sorghum, and pearl millet, in the Indian subcontinent and S.E. Asia.
In its Crop Protection unit, Devgen develops a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India) and Delaware (US) and employs more than 200 people.
Key in enabling these discoveries is the company’s ability to model these complex human diseases involving multiple organs and complex physiological processes in the model organism C. elegans in combination with the company’s associated RNAi knockdown technology. Metabolic diseases and their complications (diabetes, obesity and arrhythmia) are an important and growing disease area representing significant unmet medical needs in which the pharmaceutical industry seeks to strengthen its preclinical and clinical pipelines, paying premium prices due to the scarcity of novel concepts and programs.
Devgen believes that it should be in a position to out-license some of its programs in this area to potential partners within the next 12 to 24 months. In the event an out-licensing agreement is effectively put in place, this could provide a substantial upside for the company.
More on Devgen Human Therapeutics |
|
|